-
Something wrong with this record ?
Meloxicam, an inhibitor of cyclooxygenase-2, increases the level of serum G-CSF and might be usable as an auxiliary means in G-CSF therapy
Michal Hofer, Milan Pospíšil, Vladimír Znojil, Jiřina Holá, Antonín Vacek, Denisa Štreitová
Language English Country Czech Republic
NLK
Directory of Open Access Journals
from 1991
Free Medical Journals
from 1998
ProQuest Central
from 2005-01-01
Medline Complete (EBSCOhost)
from 2006-01-01
Nursing & Allied Health Database (ProQuest)
from 2005-01-01
Health & Medicine (ProQuest)
from 2005-01-01
ROAD: Directory of Open Access Scholarly Resources
from 1998
- MeSH
- Cell Differentiation MeSH
- Whole-Body Irradiation MeSH
- Granulocyte Colony-Stimulating Factor administration & dosage blood drug effects MeSH
- Granulocytes cytology drug effects radiation effects MeSH
- Hematopoiesis drug effects MeSH
- Cyclooxygenase 2 Inhibitors pharmacology MeSH
- Drug Therapy, Combination MeSH
- Bone Marrow drug effects radiation effects MeSH
- Drug Interactions MeSH
- Leukopenia prevention & control MeSH
- Mice, Inbred CBA MeSH
- Mice MeSH
- Thiazines pharmacology MeSH
- Thiazoles pharmacology MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
Hematopoiesis-modulating action of meloxicam, a cyclooxyge-nase-2 inhibitor, has been evaluated in mice. Increased serum level of granulocyte colony-stimulating factor (G-CSF) after meloxicam administration has been found in sublethally gamma-irradiated animals. In further experiments hematopoiesis-stimulating effects of meloxicam and G-CSF given alone or in combination have been investigated. Granulocyte/macrophage progenitor cells counts were used to monitor these effects. Meloxicam and exogenous G-CSF did not act synergistically when given in combination, but could be mutually substituted during their repeated administration. The results suggest a promising possibility of using meloxicam as an auxiliary drug reducing the high costs of G-CSF therapy of myelosuppression.
References provided by Crossref.org
Lit.: 12
- 000
- 00000naa 2200000 a 4500
- 001
- bmc07519652
- 003
- CZ-PrNML
- 005
- 20121108113516.0
- 008
- 090319s2008 xr e eng||
- 009
- AR
- 024 7_
- $a 10.33549/physiolres.931237 $2 doi
- 040 __
- $a ABA008 $b cze $c ABA008 $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Hofer, Michal $7 xx0074123
- 245 10
- $a Meloxicam, an inhibitor of cyclooxygenase-2, increases the level of serum G-CSF and might be usable as an auxiliary means in G-CSF therapy / $c Michal Hofer, Milan Pospíšil, Vladimír Znojil, Jiřina Holá, Antonín Vacek, Denisa Štreitová
- 314 __
- $a Laboratory of Experimental Hematology, Institute of Biophysics, Academy of Sciences of the Czech Republic, Brno
- 504 __
- $a Lit.: 12
- 520 9_
- $a Hematopoiesis-modulating action of meloxicam, a cyclooxyge-nase-2 inhibitor, has been evaluated in mice. Increased serum level of granulocyte colony-stimulating factor (G-CSF) after meloxicam administration has been found in sublethally gamma-irradiated animals. In further experiments hematopoiesis-stimulating effects of meloxicam and G-CSF given alone or in combination have been investigated. Granulocyte/macrophage progenitor cells counts were used to monitor these effects. Meloxicam and exogenous G-CSF did not act synergistically when given in combination, but could be mutually substituted during their repeated administration. The results suggest a promising possibility of using meloxicam as an auxiliary drug reducing the high costs of G-CSF therapy of myelosuppression.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a kostní dřeň $x účinky léků $x účinky záření $7 D001853
- 650 _2
- $a buněčná diferenciace $7 D002454
- 650 _2
- $a inhibitory cyklooxygenasy 2 $x farmakologie $7 D052246
- 650 _2
- $a lékové interakce $7 D004347
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a faktor stimulující kolonie granulocytů $x aplikace a dávkování $x krev $x účinky léků $7 D016179
- 650 _2
- $a granulocyty $x cytologie $x účinky léků $x účinky záření $7 D006098
- 650 _2
- $a hematopoéza $x účinky léků $7 D006410
- 650 _2
- $a leukopenie $x prevence a kontrola $7 D007970
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a myši $7 D051379
- 650 _2
- $a myši inbrední CBA $7 D008808
- 650 _2
- $a thiaziny $x farmakologie $7 D013843
- 650 _2
- $a thiazoly $x farmakologie $7 D013844
- 650 _2
- $a celotělové ozáření $7 D014916
- 700 1_
- $a Pospíšil, Milan, $d 1929- $7 jk01100711
- 700 1_
- $a Znojil, Vladimír, $d 1941-2008 $7 ola2003204904
- 700 1_
- $a Holá, Jiřina $7 xx0074137
- 700 1_
- $a Vacek, Antonín, $d 1929-2009 $7 jk01140948
- 700 1_
- $a Štreitová, Denisa. $7 xx0044358
- 773 0_
- $w MED00003824 $t Physiological research $g Roč. 57, č. 2 (2008), s. 307-310 $x 0862-8408
- 856 41
- $u http://www.biomed.cas.cz/physiolres/pdf/57/57_307.pdf $y plný text volně přístupný
- 910 __
- $a ABA008 $b A 4120 $c 266 $y 9
- 990 __
- $a 20090317144817 $b ABA008
- 991 __
- $a 20121108113526 $b ABA008
- 999 __
- $a ok $b bmc $g 637462 $s 490239
- BAS __
- $a 3
- BMC __
- $a 2008 $b 57 $c 2 $d 307-310 $i 0862-8408 $m Physiological research $x MED00003824
- LZP __
- $a 2009-12/mkme
